The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice

PLoS ONE

Volumn 5, Issue 1, 2010, Pages

  Tancevski, Ivan ^a   Demetz, Egon ^a   Eller, Philipp ^a   Duwensee, Kristina ^a   Hoefer, Julia ^a   Heim, Christiane ^a   Stanzl, Ursula ^a   Wehinger, Andreas ^a   Auer, Kristina ^a   Karer, Regina ^a   Huber, Julia ^a   Schgoer, Wilfried ^a   Van Eck, Miranda ^b   Vanhoutte, Jonathan ^c   Fievet, Catherine ^c   Stellaard, Frans ^d   Rudling, Mats ^e   Patsch, Josef R ^a   Ritsch, Andreas ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b LEIDEN UNIVERSITY   (Netherlands)

^c INSTITUT PASTEUR DE LILLE   (France)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN E; BILE ACID; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PLACEBO; SCAVENGER RECEPTOR BI; STEROL; T 0681; THYROMIMETIC AGENT; UNCLASSIFIED DRUG; DIPHENYL ETHER DERIVATIVE; MALONIC ACID DERIVATIVE; N (4 (3 ((4 FLUOROPHENYL)HYDROXYMETHYL) 4 HYDROXYPHENOXY) 3,5 DIMETHYLPHENYL) MALONAMIC ACID SODIUM; N-(4-(3-((4-FLUOROPHENYL)HYDROXYMETHYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) MALONAMIC ACID SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DIET; DISEASE COURSE; DRUG MECHANISM; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; FECES; LIPID METABOLISM; MACROPHAGE; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; DISEASE MODEL; DRUG EFFECT; LIVER; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

MUS; MUS MUSCULUS;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT; CHOLESTEROL; DISEASE MODELS, ANIMAL; LIVER; MALONATES; MICE; MICE, TRANSGENIC; PHENYL ETHERS;

EID: 77649284831     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008722     Document Type: Article

References (39)

1. Mason RL, Hunt HM, Hurxthal L (1930) Blood cholesterol values in hyperthyroidism and hypothyroidism. N Engl J Med 203: 1273-1278.
2. Tancevski I, Eller P, Patsch JR, Ritsch A (2009) The resurgence of thyromimetics as lipid-modifying agents. Curr Opin Investig Drugs 10: 912-918.
3. (1972) The coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The coronary drug project research group. JAMA 220: 996-1008.
4. Moreno M, de Lange P, Lombardi A, Silvestri E, Lanni A, et al. (2008) Metabolic effects of thyroid hormone derivatives. Thyroid 18: 239-253.
5. Morkin E, Ladenson P, Goldman S, Adamson C (2004) Thyroid hormone analogs for treatment of hypercholesterolemia and heart failure: past, present and future prospects. J Mol Cell Cardiol 37: 1137-1146.
6. Grover GJ, Mellstrom K, Ye L, Malm J, Li YL, et al. (2003) Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci US A 100: 10067-10072.
7. Johansson L, Rudling M, Scanlan TS, Lundasen T, Webb P, et al. (2005) Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc Natl Acad Sci U S A 102: 10297-10302.
8. Erion MD, Cable EE, Ito BR, Jiang H, Fujitaki JM, et al. (2007) Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci U S A 104: 15490-15495.
9. Berkenstam A, Kristensen J, Mellstrom K, Carlsson B, Malm J, et al. (2008) The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci U S A 105: 663-667.
10. Tancevski I, Wehinger A, Demetz E, Hoefer J, Eller P, et al. (2009) The thyromimetic T-0681 protects from atherosclerosis. J Lipid Res 50: 938-944.
11. Yu L, Li-Hawkins J, Hammer RE, Berge KE, Horton JD, et al. (2002) Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J Clin Invest 110: 671-680.
12. Miettinen TA, Tilvis RS, Kesaniemi YA (1990) Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol 131: 20-31.
13. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, et al. (2004) Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303: 1201-1204.
14. Kruit JK, Groen AK, van Berkel TJ, Kuipers F (2006) Emerging roles of the intestine in control of cholesterol metabolism. World J Gastroenterol 12: 6429-6439.
15. Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, et al. (2003) Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 108: 661-663.
16. Zhang Y, Da Silva JR, Reilly M, Billheimer JT, Rothblat GH, et al. (2005) Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest 115: 2870-2874.
17. Ritsch A, Patsch JR (2003) Cholesteryl ester transfer protein: gathering momentum as a genetic marker and as drug target. Curr Opin Lipidol 14: 173-179.
18. Baxter JD, Webb P (2009) Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 8: 308-320.
19. Krieger M (1999) Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem 68: 523-558.
20. Krieger M (2001) Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J Clin Invest 108: 793-797.
21. Wu JE, Basso F, Shamburek RD, Amar MJ, Vaisman B, et al. (2004) Hepatic ABCG5 and ABCG8 overexpression increases hepatobiliary sterol transport but does not alter aortic atherosclerosis in transgenic mice. J Biol Chem 279: 22913-22925.
22. Spady DK, Cuthbert JA, Willard MN, Meidell RS (1998) Overexpression of cholesterol 7alpha-hydroxylase (CYP7A) in mice lacking the low density lipoprotein (LDL) receptor gene. LDL transport and plasma LDL concentrations are reduced. J Biol Chem 273: 126-132.
23. Van Eck M, Bos IS, Hildebrand RB, Van Rij BT, Van Berkel TJ (2004) Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development. Am J Pathol 165: 785-794.
24. Nijstad N, Gautier T, Briand F, Rader DJ, Tietge UJ (Scientific Sessions 2009) Biliary sterol secretion is required for functional in vivo reverse cholesterol transport. Circulation 120: S443.
25. Tanigawa H, Billheimer JT, Tohyama J, Zhang Y, Rothblat G, et al. (2007) Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport. Circulation 116: 1267-1273.
26. Hayashi M, Ohnota H, Tamura T, Kuroda J, Shibata N, et al. (2004) Inhibitory effects of KAT-681, a liver-selective thyromimetic, on development of hepatocellular proliferative lesions in rats induced by 2-acetylaminofluorene and partial hepatectomy after diethylnitrosamine initiation. Arch Toxicol 78: 460-466.
27. Naik SU, Wang X, Da Silva JS, Jaye M, Macphee CH, et al. (2006) Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 113: 90-97.
28. Hulten LM, Ullstrom C, Krettek A, van Reyk D, Marklund SL, et al. (2005) Human macrophages limit oxidation products in low density lipoprotein. Lipids Health Dis 4: 6.
29. Van Eck M, Ye D, Hildebrand RB, Kar Kruijt J, de Haan W, et al. (2007) Important role for bone marrow-derived cholesteryl ester transfer protein in lipoprotein cholesterol redistribution and atherosclerotic lesion development in LDL receptor knockout mice. Circ Res 100: 678-685.
30. Wang X RM, Fuki IV, Billheimer JT, Rothblatt GH, Tall AR, Rader DJ (2006) Macrophage ABCG1 promotes reverse cholesterol transport in vivo. Circulation suppl 114: 146.
31. Hennuyer N, Tailleux A, Torpier G, Mezdour H, Fruchart JC, et al. (2005) PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol 25: 1897-1902.
32. Tancevski I, Frank S, Massoner P, Stanzl U, Schgoer W, et al. (2005) Increased plasma levels of LDL cholesterol in rabbits after adenoviral overexpression of human scavenger receptor class B type I. J Mol Med 83: 927-932.
33. Singaraja RR, Fievet C, Castro G, James ER, Hennuyer N, et al. (2002) Increased ABCA1 activity protects against atherosclerosis. J Clin Invest 110: 35-42.
34. Tancevski I,Wehinger A, Demetz E, Eller P, Duwensee K, et al. (2008) Reduced plasma high-density lipoprotein cholesterol in hyperthyroid mice coincides with decreased hepatic adenosine 5′-triphosphate-binding cassette transporter 1 expression. Endocrinology 149: 3708-3712.
35. Ritsch A, Auer B, Foger B, Schwarz S, Patsch JR (1993) Polyclonal antibody-based immunoradiometric assay for quantification of cholesteryl ester transfer protein. J Lipid Res 34: 673-679.
36. Mashige F, Imai K, Osuga T (1976) A simple and sensitive assay of total serum bile acids. Clin Chim Acta 70: 79-86.
37. Lutjohann D, Bjorkhem I, Beil UF, von Bergmann K (1995) Sterol absorption and sterol balance in phytosterolemia evaluated by deuterium-labeled sterols: effect of sitostanol treatment. J Lipid Res 36: 1763-1773.
38. Jones C, Hammer RE, Li WP, Cohen JC, Hobbs HH, et al. (2003) Normal sorting but defective endocytosis of the low density lipoprotein receptor in mice with autosomal recessive hypercholesterolemia. J Biol Chem 278: 29024-29030.
39. van der Veen JN, Kruit JK, Havinga R, Baller JF, Chimini G, et al. (2005) Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. J Lipid Res 46: 526-534.